Ranbaxy will be paid an undisclosed upfront amount, with the possibility of receiving more than Rs 400 crore associated with various research, development and regulatory approvals, the generic drug maker said.
The counter witnessed total volumes of 6.11 lakh shares against two-week average volumes of 2.09 lakh shares. The stock made an intra-day high of Rs 497 and a low of Rs 463.20.
